The Oncologist 2020;25:e1930–e1955; first published on November 7, 2020; doi: 10.1002/onco.13548
In the Additional Details of Endpoints or Study Design section of this report, it was reported that “Eight of the randomized patients had to be excluded because of sensitizing EGFR mutations or ALK translocations reported immediately after randomization (four in the homeopathy group, four in the control group).” In the parenthetical note, “control group” should have been “placebo group”. This error does not affect the results of this study, but in the interest of clarity, the online version of this article has been corrected.